Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient-Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study.

Cornford P, Jefferson K, Cole O, Gilbody J

Oncology and therapy5 Nov 2018Cited by 4 (Europe PMC)

PMID32700031PMCIDPMC7359994DOI10.1007/s40487-018-0087-1PepBankPUB-32700031

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studySafety outcome
In men with prostate cancer receiving six-monthly triptorelin, no safety issues were identified.
In plain wordsIn men with prostate cancer receiving six-monthly triptorelin, the study identified no safety issues.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSafety issues
Study
n = 88
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
No safety issues were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
Report a problemFND-3270003108
02HumanObservational studyEfficacy outcome
In men newly treated with six-monthly triptorelin for prostate cancer, median PSA was lower at follow-up than diagnosis.
In plain wordsIn men with prostate cancer, median PSA was lower after starting six-monthly triptorelin than at diagnosis.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePSA in newly treated patients
Study
n = 47
Comparator
Diagnosis
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Median PSA
1.3 ng/mL
12 months, newly treated
Median PSA
23.5 ng/mL
diagnosis, newly treated
Source sentences
Summary
At 12 months, median PSA was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 ng/mL (0.35 ng/mL at switch) for patients who had switched treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
Report a problemFND-3270003106

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In men with prostate cancer, switching to six-monthly triptorelin was linked to fewer patient reviews than prior shorter-acting treatment.
In plain wordsIn men with prostate cancer, switching to six-monthly triptorelin was linked to fewer reviews than prior shorter-acting treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePatient reviews
Study
n = 41
Comparator
Prior one- or three-monthly LHRHa
Analysis
Primary
Outcome group
Healthcare costs and utilization · Cancer
Measurements
Patient review reduction
46.8%
after switch
Source sentences
Summary
After switching to six-monthly triptorelin, there was a statistically significant reduction in patient reviews (46.8%), injections (46.8%), and PSA tests (26.6%; all P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003101
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In men with prostate cancer, switching to six-monthly triptorelin was linked to fewer injections than prior shorter-acting treatment.
In plain wordsIn men with prostate cancer, switching to six-monthly triptorelin was linked to fewer injections than prior shorter-acting treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseInjections
Study
n = 41
Comparator
Prior one- or three-monthly LHRHa
Analysis
Primary
Outcome group
Healthcare costs and utilization · Cancer
Measurements
Injection reduction
46.8%
after switch
Source sentences
Summary
After switching to six-monthly triptorelin, there was a statistically significant reduction in patient reviews (46.8%), injections (46.8%), and PSA tests (26.6%; all P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003102
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In men with prostate cancer, switching to six-monthly triptorelin was linked to fewer PSA tests than prior shorter-acting treatment.
In plain wordsIn men with prostate cancer, switching to six-monthly triptorelin was linked to fewer PSA tests than prior shorter-acting treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePSA tests
Study
n = 41
Comparator
Prior one- or three-monthly LHRHa
Analysis
Primary
Outcome group
Healthcare costs and utilization · Cancer
Measurements
PSA test reduction
26.6%
after switch
Source sentences
Summary
After switching to six-monthly triptorelin, there was a statistically significant reduction in patient reviews (46.8%), injections (46.8%), and PSA tests (26.6%; all P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003103
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In men with prostate cancer, switching to six-monthly triptorelin was linked to fewer total healthcare interactions than prior shorter-acting treatment.
In plain wordsIn men with prostate cancer, switching to six-monthly triptorelin was linked to fewer healthcare interactions than prior shorter-acting treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTotal patient-healthcare interactions
Study
n = 41
Comparator
Prior one- or three-monthly LHRHa
Analysis
Primary
Outcome group
Healthcare costs and utilization · Cancer
Measurements
Healthcare interaction reduction
41.5%
after switch
Source sentences
Summary
The total number of patient-healthcare interactions was significantly reduced (41.5%; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003104
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In men with prostate cancer, switching to six-monthly triptorelin was linked to lower interaction costs than prior shorter-acting treatment.
In plain wordsIn men with prostate cancer, switching to six-monthly triptorelin was linked to lower healthcare interaction costs than prior shorter-acting treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHealthcare interaction costs
Study
n = 41
Comparator
Prior one- or three-monthly LHRHa
Outcome group
Healthcare costs and utilization · Cancer
Measurements
Total cost reduction
10214.85 GBP
over 12 months
Cost reduction per patient
249.14 GBP
over 12 months
Source sentences
Summary
Based upon cost of these interactions only, the cost reduction of switching to six-monthly triptorelin was £10,214.85 (£249.14 per patient) over 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003105
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In men with prostate cancer who switched to six-monthly triptorelin, median PSA was lower at follow-up than at switch.
In plain wordsIn men with prostate cancer, median PSA was lower after switching to six-monthly triptorelin than at switch.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePSA in switched patients
Study
n = 41
Comparator
At switch
Outcome group
Cancer biomarkers and prognosis · Cancer
Measurements
Median PSA
0.24 ng/mL
12 months, switched
Median PSA
0.35 ng/mL
at switch
Source sentences
Summary
At 12 months, median PSA was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 ng/mL (0.35 ng/mL at switch) for patients who had switched treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres.
Summary · context
This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3270003107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.